Hepatitis C Hopeful PPI-461 Getting Good Marks in Phase 1b Trial

[Guest guest]

Hepatitis C Hopeful PPI-461 Getting Good Marks in Phase 1b Trial

Interim safety and efficacy data on Presidio's NS5A inhibitor, PPI-461, indicates that this novel drug could be a top Hepatitis C therapy contender.

Presidio Pharmaceuticals, Inc. Announces Positive Results in a Phase 1b Clinical Trial of PPI-461, a Novel, Potent Broadly-Active Hepatitis C Virus (HCV) Inhibitor

Mar. 30, 2011 (Business Wire) -- Presidio Pharmaceuticals, Inc. announced today positive preliminary results from a Phase 1b clinical trial of PPI-461, a novel HCV NS5A inhibitor for the treatment of patients with chronic hepatitis C.

The PPI-461 phase 1b clinical trial reported here is a multiple ascending dose, randomized, blinded, placebo-controlled study in treatment-naïve adult hepatitis C patients with HCV genotype-1 infection; this trial is presently ongoing in the U.K., Denmark, and the United States. The study objectives are to assess the safety, tolerability, pharmacokinetics, and initial antiviral effects of PPI-461 during once-daily (QD) dosing at three dosing levels (50, 100, and 200 mg/day) for three days. Each dosing cohort of 8 patients is randomized 6 (PPI-461):2 (placebo). Two dosing groups have completed study treatment to date; the third (200 mg) dosing group is ongoing.

Continue reading this entire article:http://www.istockanalyst.com/business/news/5019831/presidio-pharmaceuticals-inc-announces-positive-results-in-a-phase-1b-clinical-trial-of-ppi-461-a-novel-potent-broadly-active-hepatitis-c-virus-hcv-inhibitor

http://www.hepatitis-central.com/mt/archives/2011/03/hepatitis_c_hop_1.html